At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 48 enrolled
Drug / intervention
Azithromycin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration
In Brief
A Phase 4 clinical trial evaluating Azithromycin and Moxifloxacin for Bacterial Infections and Eye Infections. Completed, enrolled 48 participants.
Detailed Summary
The purpose of this study is to evaluate the drug concentrations of AzaSite™ compared to Vigamox at various time points in conjunctiva tissue of healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections, Eye Infections
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartDec 2007
Primary CompletionDec 2007
TodayJul 2026
First PostedNov 28, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 18.6 years ago
Interventions
Azithromycindrug
azithromycin topical solution 1% given as a single drop in a single eye
Moxifloxacindrug
Moxifloxacin topical solution given as a single drop in a single eye